Skip to content

Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System

Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System: a Monocentric Post-market Observational Study

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03379714
Enrollment
0
Registered
2017-12-20
Start date
2018-01-01
Completion date
2022-01-31
Last updated
2018-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ruptured and Unruptured Intracranial Aneurysms

Brief summary

Flow disruption is a new endovascular approach for treatment of both ruptured and unruptured intracranial aneurysms, which involves placement of an endosaccular device (WEB) which modifies the blood flow at the level of the neck and induces intraaneurysmal thrombosis. The WEB was designed to treat wide-neck bifurcation aneurysms. This observational study will collect data about the routine practice in one center of using the WEB in ruptured and unruptured intracranial aneurysms. The primary objective is to evaluate its efficacy by assessing the anatomic outcome during follow-up.

Interventions

The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.

Sponsors

Archer Research
CollaboratorINDUSTRY
Medical Therapy Solutions
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient is at least 18 years old. 2. Patient is capable to undergo general anaesthesia. 3. Patient must sign and date the informed consent form prior to data registration. If patient is not able to give informed consent for himself/herself, a legally authorized representative must give informed consent on his/her behalf. 4. Patient has a ruptured or unruptured intracranial aneurysm requiring endovascular treatment. 5. Aneurysm with dome-to-neck ratio ≥ 1. 6. Aneurysm size favourable for WEB implantation (aneurysm width \< 10 mm or aneurysm width \> 3mm).

Exclusion criteria

1. Patient is pregnant. 2. Patient has renal insufficiency (GRF \< 45 ml/min/1.73 m2). 3. Patient is unable to comply with the study protocol (e.g. no permanent address, known to be non-compliant or presenting an unstable psychiatric history).

Design outcomes

Primary

MeasureTime frameDescription
Determination of anatomic outcomeat 6 monthsgrade of occlusion of the aneurysm assessed by MRA WEB Occlusion Scale: WOS A: complete occlusion WOS B: complete occlusion with opacification of the proximal recess WOS C: residual neck filling WOS D: residual aneurysm filling

Secondary

MeasureTime frameDescription
Recording the use of additional devices during treatment.during index-procedurePossible additional devices are stent, coils, flow diverter
Determination of the occurrence of post-procedural symptomatic thromboembolic eventsup to 24 months follow-up
Determination of clinical outcome: assessing disability of the patient by the modified Rankin Scale (mRS)At baseline0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead.
Fisher grade (severity of intracranial SAH) for ruptured aneurysms.at baselineFisher grade: 1 No haemorrhage evident. 2 Subarachnoid haemorrhage less than 1mm thick. 3 Subarachnoid haemorrhage more than 1mm thick. 4 Subarachnoid haemorrhage of any thickness with intraventricular haemorrhage (IVH) or parenchymal extension.
Determination of procedural complications (Adverse events) during the operationduring index-procedureProcedural complications: aneurysm rupture, dissection, thromboembolic events (symptomatic and non-symptomatic), device protrusion through the neck of the aneurysm inside the parent artery, detachment problem, device stuck in microcatheter, bleeding.
Determination of overall mortalityup to 24 months
Recording of intracranial haemorrhage during follow-upup to 24 months
Recording the need for re-intervention during follow-up.up to 24 months
Hunt and Hess scale (severity of clinical effect of SAH) for ruptured aneurysms.baselineHunt and Hess scale: 1. asymptomatic or minimal headache and slight neck stiffness, 70% survival 2. moderate to severe headache; neck stiffness; no neurologic deficit except cranial nerve palsy; 60% survival 3. drowsy; minimal neurologic deficit; 50% survival 4. stuporous; moderate to severe hemiparesis; possibly early decerebrate rigidity and vegetative disturbances; 20% survival 5. deep coma; decerebrate rigidity; moribund;10% survival
Determination of technical success of the deviceduring index-procedureTechnical success is defined as device deployment in the target aneurysm as intended by the investigator with adequate occlusion of the aneurysm (WOS A, B or C).

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026